OA08.04 Active tuberculosis co-infection enhances HIV-1 specific humoral immunityOral Abstract SessionHumoral immunity
OA13.03 Acceptability of telemedicine and HIV self-test among PrEP users during the COVID-19 pandemic in BrazilOral Abstract SessionImplementation science, including structural interventions, PrEP & VMMC
OA12.04LB A VSV-based HIV-1 vaccine provides protection in macaques against low dose cross-clade SHIVenv_SF162_P3 challengeOral Abstract SessionNovel vaccine and other prevention approaches
OA17.02 A synergistic model of engagement: the ECHO Global Community Advisory Group and HC-HIV Advocacy Working GroupOral Abstract SessionCommunity engagement in prevention research
OA16.05 A randomized, double blind, placebo-controlled, phase 1 safety and pharmacokinetic study of dapivirine gel (0.05%) administered rectally to HIV-1 seronegative adults (MTN-026)Oral Abstract SessionPharmacology/PK and PD studies
PE06.05 A randomized group antenatal care pilot showed increased partner communication and partner HIV testing during pregnancy in Malawi and TanzaniaE-posterContraception, pregnancy and HIV prevention (incl. PMTCT)
OA06.05 A phase I study to assess safety, pharmacokinetics and pharmacodynamics of a topical multipurpose prevention insert containing tenofovir alafenamide fumarate and elvitegravir dosed vaginallyOral Abstract SessionClinical trial results
PE08.07 A new multipurpose vaginal ring for prevention of HIV and treatment of bacterial vaginosisE-posterDelivery technologies: novel approaches, formulation and multi-purpose
OA11.02 A multi-country investigation of Pre-Exposure Prophylaxis preferences among young people at risk of HIV in sub-Saharan Africa Oral Abstract SessionHumoral immunity
PE02.17LB A lineage of exceptionally potent and broad BnAbs with ultralong CDRH3 from vaccinated cows focus low-mutation rate from germline into a globular knob contacting the CD4bsE-posterBroadly neutralizing antibodies
seek-warrow-warrow-eseek-e431 - 440 of 444 items